Richard Quinn is a freelance writer in New Jersey.
Reference
1. Yazdany J, Dudley RA, Chen R, et al. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare part D. 2015. Arthritis Rheumatol. Jun;67(6):1474–1480.
Related Articles
Medicare D-lemmas
Rheumatologists and patients report mixed experiences with the new prescription drug benefit
Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…
Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
Choosing Wisely: Recommendations from Medical Specialties Beyond Rheumatology
Practice gems that may help rheumatologists avoid performing costly patient tests, procedures of limited use